REDWOOD CITY, Calif.--(BUSINESS WIRE)--Maxygen, Inc. (Nasdaq:MAXY), a biotechnology company focused on the development of improved protein drugs, today announced that its distributions of Codexis, Inc. (Nasdaq: CDXS) common stock and cash in December 2010 will be classified as a return of capital to its stockholders for U.S. Federal income tax purposes.
